Oct 2026· Journal of Clinical Investigation· Vol 136· 0 citations· 176 references
Medicine
TL;DR
The biological basis and translational challenges of de novo and acquired resistance related to targets, payloads, and tumor microenvironmental constraints, as well as the implications of these mechanisms for biomarker development, sequencing rationales, and combination strategies with immune checkpoint inhibitors and DNA repair–targeting therapies are discussed.
Abstract
Antibody-drug conjugates (ADCs) have transformed the treatment landscape of breast cancer and redefined the conceptual distinction between targeted therapy and conventional chemotherapy. Originally conceived as “magic bullets” that selectively deliver cytotoxic warheads to antigen-expressing tumor cells, clinical and mechanistic evidence indicates that ADC activity depends on a broader interplay of target-dependent and target-independent mechanisms, including extracellular payload release, bystander killing, off-tumor uptake, and immune modulation. Here, we examine ADCs in breast cancer as a distinct therapeutic paradigm. We discuss how antigen biology, linker chemistry, payload features, and drug-to-antibody ratio collectively determine efficacy, toxicity, and therapeutic index. We then compare currently approved and emerging HER2- and TROP2-directed ADCs, highlighting how differences in linker stability, payload pharmacology, and bystander capacity can affect clinical outcomes in ADCs sharing the same target. We further discuss the biological basis and translational challenges of de novo and acquired resistance related to targets, payloads, and tumor microenvironmental constraints, as well as the implications of these mechanisms for biomarker development, sequencing rationales, and combination strategies with immune checkpoint inhibitors and DNA repair–targeting therapies. Finally, we outline future directions of ADC development, including expansion of the target space, novel payload modalities, and next-generation antibody and conjugation engineering.
Three principles emerge: ADC efficacy is a systems property; strategies that broaden tumor coverage may also increase normal-tissue exposure; and successful combinations require platform-specific rather than class-wide rationale.
Shi-Yan Zeng, Li Wang, Wan-Qin Zeng et al.· Drug Design, Development and...· 0 citations
Antibody-drug conjugates (ADCs) have progressively advanced the conceptual framework of targeted oncology, evolving from a way to deliver chemotherapy selectively to tumor cells into drugs that also interact with the immune system to support their action. In breast cancer, the approval of several novel ADCs has transfo...
A. Mattana, C. Veronese, Julia Penitenti et al.· Frontiers in Immunology· 0 citations
Next-generation ADCs may function not only as targeted cytotoxic agents but also as modulators of antitumor immunity in gastric cancer, and integrating tumor-antigen biology with immune-contextual features may enable more rational patient selection and therapeutic combinations.
Hong-Hua Su, Chun-Yin Yang, Jia-Yun Ge· Frontiers in Immunology· 0 citations
This review focuses on the research progress of ADCs targeting non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), providing an in-depth analysis of their mechanisms of action, molecular design, and clinical efficacy, with particular emphasis on novel ADCs targeting HER2, TROP2, and DLL3.
Yi-Lin Zhao, Xiao-Ran Ma, Xiao-Zhen Liu et al.· Cancer Chemotherapy and Phar...· 0 citations
Monoclonal antibodies (mAbs) are a cornerstone of cancer therapy. They offer high target specificity and diverse cytotoxic mechanisms, which render them superior to many conventional cytotoxic treatments. This review examines therapeutic mAbs from two aspects. First, their mechanisms of action are analysed, including d...
Ye-Mei Chen· Theoretical and Natural Scie...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.